Log in
Login
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  MorphoSys AG    MOR   DE0006632003

End-of-day quote. End-of-day quote  - 05/04
43.425 EUR   +0.60%
05/04 MORPHOSYS : to Present at Three Upcoming Conferences
05/03 MORPHOSYS : AG Reports Results for the First Three Months of 2016
04/27 MORPHOSYS : to Host Q1 2016 Conference Call on May 3, 2016
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

MORPHOSYS : to Present at Upcoming Investor Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/02/2011 | 04:05pm CEST

MorphoSys AG / MorphoSys to Present at Upcoming Investor Conference Processed and transmitted by Thomson Reuters. The issuer is solely responsible for the content of this announcement.

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX) announced today that Chief Executive Officer Dr Simon Moroney will present at the upcoming Société Générale Healthcare and Biotechnology Conference in Paris.

 

Société Générale Healthcare and Biotechnology Conference
Date: February 9, 2011
Venue: Paris, France
Presenter: Dr. Simon Moroney, CEO of MorphoSys AG

 

A PDF version of the company presentation is provided at www.morphosys.com:
http://www.morphosys.com/

 

 

 

 

+++MorphoSys will publish its Full Year 2010 Results on February 24, 2011+++

 

 

About MorphoSys:
MorphoSys is an independent biotechnology company that develops novel antibodies for therapeutic, diagnostic and research applications. The Company's HuCAL technology is one of the most powerful methods available for generating fully human antibodies. By successfully applying this and other proprietary technologies, MorphoSys has become a leader in the field of therapeutic antibodies, one of the fastest-growing drug classes in human health-care. Through its alliances with some of the world's leading pharmaceutical companies, MorphoSys has created a pipeline of more than 60 drug candidates. The Company is expanding its drug pipeline by adding new partnered programs, and by building a portfolio of fully-owned therapeutic antibodies. For its proprietary portfolio, the Company is focused on the areas of oncology and inflammation. Its most advanced program MOR103, a first-in-class, fully human antibody against GM-CSF, is currently being tested in a Phase Ib/IIa trial in rheumatoid arthritis patients. Via its business unit AbD Serotec, MorphoSys is expanding the reach of its technologies in the diagnostics and research markets. MorphoSys is headquartered in Munich, Germany and listed on the Frankfurt Stock Exchange under the symbol "MOR". For further information, visit http://www.morphosys.com/:
http://www.morphosys.com/

 

HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay® and RapMAT® are registered trademarks of MorphoSys. arYlaTM is a trademark of MorphoSys.

 

 

This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.

 

 

 

 

For more information, please contact:

MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-122

 

Mario Brkulj
Senior Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-454

 

Jessica Kulpi
Specialist Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-332

 

investors@morphosys.com:
mailto:investors@morphosys.com

 

Press Release:
http://hugin.info/130295/R/1484742/419929.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: MorphoSys AG via Thomson Reuters ONE


HUG#1484742


share with twitter share with LinkedIn share with facebook
share via e-mail
0
React to this article
Latest news on MORPHOSYS AG
05/04 MORPHOSYS : to Present at Three Upcoming Conferences
05/03 MORPHOSYS : AG Reports Results for the First Three Months of 2016
04/27 MORPHOSYS : to Host Q1 2016 Conference Call on May 3, 2016
04/21 MORPHOSYS AG : MorphoSys Provides Update on Results From Partner's Phase 2b/3 RE..
04/21 AD HOC : MorphoSys Provides Update on Results From Partner's Phase 2b/3 RESILIEN..
04/20 MORPHOSYS : Licensing Partner GSK Starts Phase 2 Study with GSK3196165 (MOR103) ..
04/20 MORPHOSYS AG : Announcement of the Convening of the AGM in Munich/Germany on Jun..
04/18 MORPHOSYS : Licensing Partner GSK Starts Phase 2 Study with GSK3196165 (MOR103) ..
04/09 MORPHOSYS : and Galapagos Initiate Phase 1 Study in Joint Antibody Program MOR10..
04/08 GALAPAGOS : and MorphoSys initiate Phase 1 study in joint antibody program MOR10..
Advertisement
News chart
Full-screen chart
Income Statement Evolution
More Financials